Nuvation Bio NUVB Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Questions, answered.
- What is Nuvation Bio's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss?
- Nuvation Bio (NUVB) reported debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss of $0 in Q4 2025.
- How has Nuvation Bio's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss changed year-over-year?
- Nuvation Bio's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss decreased by 100.0% year-over-year, from $129K to $0.